Fmr LLC grew its stake in CytomX Therapeutics Inc (NASDAQ:CTMX) by 0.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,843,626 shares of the biotechnology company’s stock after acquiring an additional 51,953 shares during the quarter. Fmr LLC owned 0.13% of CytomX Therapeutics worth $133,586,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in CTMX. UBS Group AG increased its stake in shares of CytomX Therapeutics by 311.3% during the 1st quarter. UBS Group AG now owns 45,937 shares of the biotechnology company’s stock worth $1,307,000 after purchasing an additional 34,767 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of CytomX Therapeutics during the 1st quarter worth $205,000. Allianz Asset Management GmbH increased its stake in shares of CytomX Therapeutics by 7.4% during the 1st quarter. Allianz Asset Management GmbH now owns 58,739 shares of the biotechnology company’s stock worth $1,671,000 after purchasing an additional 4,036 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth $206,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth $502,000. 71.53% of the stock is currently owned by institutional investors and hedge funds.
Shares of CTMX opened at $12.75 on Wednesday. CytomX Therapeutics Inc has a 12 month low of $12.75 and a 12 month high of $35.00. The firm has a market cap of $674.91 million, a PE ratio of -10.99 and a beta of 1.46.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.11). CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. Research analysts forecast that CytomX Therapeutics Inc will post -1.58 earnings per share for the current year.
Several research analysts have recently commented on CTMX shares. Zacks Investment Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Tuesday, July 10th. BidaskClub lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. ValuEngine lowered shares of CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 29th. HC Wainwright started coverage on shares of CytomX Therapeutics in a research note on Thursday, September 13th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Goldman Sachs Group started coverage on shares of CytomX Therapeutics in a research note on Monday, October 15th. They set a “neutral” rating and a $21.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $34.88.
In related news, CFO Debanjan Ray sold 3,000 shares of the company’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $18.46, for a total transaction of $55,380.00. Following the completion of the sale, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at approximately $164,810.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Sean A. Mccarthy sold 13,052 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $21.86, for a total transaction of $285,316.72. Following the sale, the insider now directly owns 95,115 shares of the company’s stock, valued at $2,079,213.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,578 shares of company stock valued at $550,757. 8.50% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Fmr LLC Grows Position in CytomX Therapeutics Inc (CTMX)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/07/fmr-llc-grows-position-in-cytomx-therapeutics-inc-ctmx.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: Marijuana Stocks
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.